Exploring immunotherapeutic strategies for neurodegenerative diseases: a focus on Huntington's disease and Prion diseases

被引:0
作者
Mukherjee, Abhiyanta [1 ]
Biswas, Soumojit [1 ]
Roy, Ipsita [1 ]
机构
[1] Natl Inst Pharmaceut Educ & Res, Dept Biotechnol, Sas Nagar, Punjab, India
来源
ACTA PHARMACOLOGICA SINICA | 2025年
关键词
immunotherapy; Huntingtons disease; Prion disease; protein aggregation; vaccination; CREUTZFELDT-JAKOB-DISEASE; YAC128 MOUSE MODEL; TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY; INTRAVENTRICULAR PENTOSAN POLYSULFATE; HUMORAL IMMUNE-RESPONSE; PROLONGS SURVIVAL TIMES; LAMININ RECEPTOR ACTS; ACCUMULATION IN-VITRO; WHITE-TAILED DEER; WILD-TYPE MICE;
D O I
10.1038/s41401-024-01455-w
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Immunotherapy has emerged as a promising therapeutic approach for the treatment of neurodegenerative disorders, which are characterized by the progressive loss of neurons and impaired cognitive functions. In this review, active and passive immunotherapeutic strategies that help address the underlying pathophysiology of Huntington's disease (HD) and prion diseases by modulating the immune system are discussed. The current landscape of immunotherapeutic strategies, including monoclonal antibodies and vaccine-based approaches, to treat these diseases is highlighted, along with their potential benefits and mechanisms of action. Immunotherapy generally works by targeting disease-specific proteins, which serve as the pathological hallmarks of these diseases. Additionally, the review addresses the challenges and limitations associated with immunotherapy. For HD, immunotherapeutic approaches focus on neutralizing the toxic effects of mutant huntingtin and tau proteins, thereby reducing neurotoxicity. Immunotherapeutic approaches targeting flanking sequences, rather than the polyglutamine tract in the mutant huntingtin protein, have yielded promising outcomes for patients with HD. In prion diseases, therapies attempt to prevent or eliminate misfolded proteins that cause neurodegeneration. The major challenge in prion diseases is immune tolerance. Approaches to overcome the highly tolerogenic nature of the prion protein have been discussed. A common hurdle in delivering antibodies is the blood-brain barrier, and strategies that can breach this barrier are being investigated. As protein aggregation and neurotoxicity are related, immunotherapeutic strategies being developed for other neurodegenerative diseases could be repurposed to target protein aggregation in HD and prion diseases. While significant advances in this field have been achieved, continued research and development are necessary to overcome the existing limitations, which will help in shaping the future of immunotherapy as a strategy for managing neurological disorders.
引用
收藏
页码:1511 / 1538
页数:28
相关论文
共 327 条
  • [41] Polyglutamine disease proteins: Commonalities and differences in interaction profiles and pathological effects
    Bonsor, Megan
    Ammar, Orchid
    Schnoegl, Sigrid
    Wanker, Erich E.
    Ramos, Eduardo Silva
    [J]. PROTEOMICS, 2024, 24 (12-13)
  • [42] Toxic effects of mutant huntingtin in axons are mediated by its proline-rich domain
    Brady, Scott T.
    Mesnard-Hoaglin, Nichole A.
    Mays, Sarah
    Priego, Mercedes
    Dziechciowska, Joanna
    Morris, Sarah
    Kang, Minsu
    Tsai, Ming Ying
    Purks, Jennifer L.
    Klein, Alison
    Gaona, Angelica
    Melloni, Alexandra
    Connors, Theresa
    Hyman, Bradley
    Song, Yuyu
    Morfini, Gerardo A.
    [J]. BRAIN, 2024, 147 (06) : 2098 - 2113
  • [43] Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial
    Brownstein, Michael J.
    Simon, Neal G.
    Long, Jeffrey D.
    Yankey, Jon
    Maibach, Hilda T.
    Cudkowicz, Merit
    Coffey, Christopher
    Conwit, Robin A.
    Lungu, Codrin
    Anderson, Karen E.
    Hersch, Steven M.
    Ecklund, Dixie J.
    Damiano, Eve M.
    Itzkowitz, Debra E.
    Lu, Shifang
    Chase, Marianne K.
    Shefner, Jeremy M.
    McGarry, Andrew
    Thornell, Brenda
    Gladden, Catherine
    Costigan, Michele
    O'Suilleabhain, Padraig
    Marshall, Frederick J.
    Chesire, Amy M.
    Deritis, Paul
    Adams, Jamie L.
    Hedera, Peter
    Lowen, Kelly
    Rosas, H. Diana
    Hiller, Amie L.
    Quinn, Joseph
    Keith, Kellie
    Duker, Andrew P.
    Gruenwald, Christina
    Molloy, Angela
    Jacob, Cara
    Factor, Stewart
    Sperin, Elaine
    Bega, Danny
    Brown, Zsazsa R.
    Seeberger, Lauren C.
    Sung, Victor W.
    Benge, Melanie
    Kostyk, Sandra K.
    Daley, Allison M.
    Perlman, Susan
    Suski, Valerie
    Conlon, Patricia
    Barrett, Matthew J.
    Lowenhaupt, Stephanie
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11) : 1 - 14
  • [44] Prion diseases: immunotargets and therapy
    Burchell, Jennifer T.
    Panegyres, Peter K.
    [J]. IMMUNOTARGETS AND THERAPY, 2016, 5 : 57 - 68
  • [45] Emergence of prions selectively resistant to combination drug therapy
    Burke, Cassandra M.
    Mark, Kenneth M. K.
    Kun, Judit
    Beauchemin, Kathryn S.
    Supattapone, Surachai
    [J]. PLOS PATHOGENS, 2020, 16 (05)
  • [46] Bifunctional Anti-Huntingtin Proteasome-Directed Intrabodies Mediate Efficient Degradation of Mutant Huntingtin Exon 1 Protein Fragments
    Butler, David C.
    Messer, Anne
    [J]. PLOS ONE, 2011, 6 (12):
  • [47] Prion protein β2-α2 loop conformational landscape
    Caldarulo, Enrico
    Barducci, Alessandro
    Wuthrich, Kurt
    Parrinello, Michele
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (36) : 9617 - 9622
  • [48] Phosphatidylethanolamine Metabolism in Health and Disease
    Calzada, Elizabeth
    Onguka, Ouma
    Claypool, Steven M.
    [J]. INTERNATIONAL REVIEW OF CELL AND MOLECULAR BIOLOGY, VOL 321, 2016, 321 : 29 - 88
  • [49] Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease
    Caron, Nicholas S.
    Southwell, Amber L.
    Brouwers, Cynthia C.
    Dal Cengio, Louisa
    Xie, Yuanyun
    Black, Hailey Findlay
    Anderson, Lisa M.
    Ko, Seunghyun
    Zhu, Xiang
    van Deventer, Sander J.
    Evers, Melvin M.
    Konstantinova, Pavlina
    Hayden, Michael R.
    [J]. NUCLEIC ACIDS RESEARCH, 2020, 48 (01) : 36 - 54
  • [50] The anti-prion activity of Congo red - Putative mechanism
    Caspi, S
    Halimi, M
    Yanai, A
    Ben Sasson, S
    Taraboulos, A
    Gabizon, R
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (06) : 3484 - 3489